Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by PDT Partners LLC

PDT Partners LLC trimmed its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 6.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,109 shares of the company's stock after selling 17,164 shares during the quarter. PDT Partners LLC owned 0.32% of Travere Therapeutics worth $4,305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in TVTX. Sterling Capital Management LLC lifted its holdings in shares of Travere Therapeutics by 859.8% during the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after purchasing an additional 2,115 shares during the period. R Squared Ltd acquired a new stake in Travere Therapeutics in the 4th quarter valued at $53,000. Summit Investment Advisors Inc. increased its stake in shares of Travere Therapeutics by 9.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock worth $138,000 after purchasing an additional 667 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Travere Therapeutics during the 4th quarter worth approximately $182,000. Finally, Baader Bank Aktiengesellschaft purchased a new stake in shares of Travere Therapeutics during the fourth quarter worth approximately $192,000.

Insider Buying and Selling

In related news, CAO Sandra Calvin sold 54,244 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the sale, the chief accounting officer now owns 54,410 shares of the company's stock, valued at approximately $1,360,250. This represents a 49.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP William E. Rote sold 8,951 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $19.78, for a total transaction of $177,050.78. Following the completion of the transaction, the senior vice president now directly owns 95,719 shares in the company, valued at approximately $1,893,321.82. This represents a 8.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,330 shares of company stock worth $3,507,377 in the last quarter. Company insiders own 4.06% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Citigroup raised their target price on Travere Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, February 24th. Guggenheim reiterated a "buy" rating and issued a $47.00 price objective on shares of Travere Therapeutics in a report on Monday, April 14th. Evercore ISI raised their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Canaccord Genuity Group boosted their price target on shares of Travere Therapeutics from $45.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. Finally, Scotiabank reiterated an "outperform" rating on shares of Travere Therapeutics in a research note on Friday, April 11th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.08.

Travere Therapeutics Stock Down 0.2 %

Shares of TVTX traded down $0.05 during mid-day trading on Thursday, reaching $20.76. The company's stock had a trading volume of 1,917,028 shares, compared to its average volume of 1,519,633. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a 12-month low of $5.79 and a 12-month high of $25.29. The stock has a market cap of $1.84 billion, a PE ratio of -5.06 and a beta of 0.84. The company's 50 day moving average is $18.07 and its 200 day moving average is $18.71.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. During the same period in the previous year, the firm posted ($1.76) earnings per share. The company's revenue was up 83.3% compared to the same quarter last year. Equities analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.